The efficacy of tucatinib-based therapeutic approaches for HER2-positive breast cancer
Overexpression of human epidermal growth factor receptor 2 (HER2) occurs in approximately 15–20% of breast cancer cases. HER2 is a member of the epidermal growth factor receptor (EGFR) family with tyrosinase k...